Newland Pharmaceutical Co., Ltd. (SHE:301277)

Newland Pharmaceutical Revenue

Newland Pharmaceutical had revenue of 190.03M CNY in the quarter ending June 30, 2026, with 36.69% growth. This brings the company's total for the last twelve months to 710.55M, up 3.20% year-over-year. In the year 2025, Newland Pharmaceutical had annual revenue of 672.38M, down -7.44%. That makes Newland Pharmaceutical the 22,179th largest company in the world by revenue and 4,043rd in China.

• Revenue (ttm): 710.55M
• Revenue Growth: +3.20%
• P/S Ratio: 5.27
• Revenue / Employee: 724.31K
• Employees: 981
• Market Cap: 3.74B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Intermediates 657.85M 97.8%
• Other 14.53M 2.2%

By Geography

Chart

• China 668.43M 99.4%
• Foreign 3.95M 0.6%

Fiscal year ended Dec 31, 2025 See the full Newland Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	672.38M	-54.06M	-7.44%
Dec 31, 2024	726.44M	75.00M	11.51%
Dec 31, 2023	651.44M	24.07M	3.84%
Jan 1, 2023	627.36M	113.53M	22.09%
Jan 1, 2022	513.84M	80.71M	18.64%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error